May 23, 2017 07:46 AM EDTUpdated May 23, 10:45 PM

Adam Koppel and Jeff Schwartz are done raising capital. Now they have $720M to do some serious deals at Bain

John Carroll

Editor & Founder

When Adam Koppel looped back to Bain Capital last summer, where he had already wired himself into the healthcare finance field, he immediately paired back …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Adam Koppel and Jeff Schwartz are done raising capital. Now they have $720M to do some serious deals at Bain

John Carroll

Editor & Founder

Sign up to read this article for free.

Applied Therapeutics' rare disease drug gets a CRL

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

To lead NIH, Trump taps Stanford academic and pandemic response critic Jay Bhattacharya

Novartis to cut 139 jobs in NJ as part of commercial refocus

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy

Trump team asked Warp Speed leader to head NIH, may seek more traditional pick for role

Adam Kop­pel and Jeff Schwartz are done rais­ing cap­i­tal. Now they have $720M to do some se­ri­ous deals at Bain

John Carroll

Editor & Founder

Sign up to read this article for free.

more like this

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

Trump team asked Warp Speed leader to head NIH, may seek more tra­di­tion­al pick for role

Adam Koppel and Jeff Schwartz are done raising capital. Now they have $720M to do some serious deals at Bain

Applied Therapeutics' rare disease drug gets a CRL

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

To lead NIH, Trump taps Stanford academic and pandemic response critic Jay Bhattacharya

Novartis to cut 139 jobs in NJ as part of commercial refocus

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy

Trump team asked Warp Speed leader to head NIH, may seek more traditional pick for role